CNBC
04 Nov 2026, 06:43 UTC · 25m ago
Novo raises full-year outlook as Wegovy sales impress
Impact · against what's priced in
Novo Nordisk's stronger-than-expected Wegovy performance and outlook upgrade create a slight headwind for Eli Lilly. The news validates the competitive risk from Novo's oral options that the market has not yet fully priced into Lilly's valuation.
- LLY−0.20
Challenges what's priced in
- The price assumes
The bear case that GLP-1 concentration risk and competitive pressure from Novo Nordisk's oral Wegovy will compress margins
The price currently discounts the risk of competitive pressure from Novo's oral Wegovy; the fact that Novo's pill 'blew past estimates' and drove a guidance upgrade suggests this competitive threat is materializing faster than the current price assumes.
What LLY's price assumes · Sep 10
Top 1 mover · tap to explore
